Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

• Status: Terminated
• Trial end date: 2020-09-25
• Target enrollment: 0
• Participant gender: All

Summary

Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention group will receive degludec. The investigators will call participants monthly and see them in the clinic every three months.The investigators will follow them for 1 year and evaluate if there will be a difference in rate of DKA in between these two groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hennepin Healthcare Research Institute; Minneapolis Medical Research Foundation
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

Patients age >18 year with previous diagnosis of Diabetes Mellitus and previous admission for DKA in any facility within the prior 2 years who meet the criteria for DKA at the time of admission and are willing to participate in the study protocol will be enrolled in the study.

DKA is defined as:

1. Serum bicarbonate below 18 mg/dl

2. Anion Gap over greater than or equal to 16

3. Serum ketones or beta hydroxybutyrate elevation > 3 mmol/L

4. Serum glucose greater than or equal to 250 mg/dl

Exclusion Criteria:

Patients with no previous DKA, patients who are not willing to consent to participate in the study protocol for 1 year, pregnant women, dementia, and end stage renal disease on dialysis.

-